In pursuit of developing innovative weight-loss treatments, GLP-1 and GIP are on focus in the fight against obesity, as different drugs are designed to mimic their effect on the regulation of glucose homeostasis, satiety, and energy balance.
Obesity is a major health problem worldwide, with a rapid increase in the last decades and an estimated global prevalence of one billion people by 2030.
The gastrointestinal peptides GLP-1 and GIP are crucial players in the field of metabolic diseases. These hormones, released post-meal, stimulate insulin secretion, suppress glucagon release, and promote satiety. By understanding how the abnormal secretion of these molecules can lead to metabolic diseases it may be possible to identify new more efficient drug targets, offering potential avenues for more effective treatments.
Precision measurement techniques, such as antibody-based technologies like ELISA, are essential for analyzing variations in hormone levels influenced by individual phenotypes or metabolic conditions.
At Mercodia, we are at the forefront of providing cutting-edge assays for gut hormones, enabling researchers and healthcare professionals to investigate deeper into the complexities of metabolic diseases.
GLP-1
The Mercodia Total GLP-1 ELISA provides a chemiluminescent method for the quantitative determination of amidated GLP-1 in human plasma and serum samples. The assay has been validated according to CLSI, FDA, and EMA guidelines.
GIP
The Mercodia Total GIP ELISA provides a method for the quantitative determination of total GIP in human samples. Total GIP ELISA has no cross-reactivity to known cross-reactants such as GLP-1, glucagon, oxyntomodulin, and glicentin.
We gladly support you by keeping you updated on our latest products and the developments around our services.
Direct contact technical support
Find products for your research
